Oncology Advertising

Article

For the past 25 years ONCOLOGY has kept pace with the progression of the oncology field and has offered an interpretation of literature which appeals to both the academician and the practicing "in-the-trenches" community oncologist. Its unique editorial platform consists of clinical and practical review articles followed by 2-3 expert commentaries. The journal's review articles are authored by top physicians in their respective specialties and address important issues and questions such as: interpretations and reviews of the latest and sometimes controversial-research; and new "takes" on persistent unresolved problems. Editorial features such as Practice & Policy, explore the changing times in the healthcare landscape in such areas as FDA regulations, Medicare & Medicaid policy, and the impact of health care reform. Another feature is Integrative Oncology which covers alternative herbal treatments, uses, research, adverse reactions and interactions. ONCOLOGY serves as a strong resource and forum for the cancer care clinician and generates a strong sense of community among its readers. Click here to view our media kit/rate card.Publisher and Sales Contacts:Amy BirnbachGroup PublisherPh: 201-984-6265Email: amy.birnbach@ubm.comSarah MifsudAccount ManagerDigital MediaPh: 203-523-7055Email: sarah.mifsud@ubm.com

ADVERTISING

For the past 25 years ONCOLOGY has kept pace with the progression of the oncology field and has offered an interpretation of literature which appeals to both the academician and the practicing "in-the-trenches" community oncologist.

Its unique editorial platform consists of clinical and practical review articles followed by 2-3 expert commentaries. The journal's review articles are authored by top physicians in their respective specialties and address important issues and questions such as: interpretations and reviews of the latest and sometimes controversial-research; and new "takes" on persistent unresolved problems.

Editorial features such as Practice & Policy, explore the changing times in the healthcare landscape in such areas as FDA regulations, Medicare & Medicaid policy, and the impact of health care reform. Another feature is Integrative Oncology which covers alternative herbal treatments, uses, research, adverse reactions and interactions.

ONCOLOGY serves as a strong resource and forum for the cancer care clinician and generates a strong sense of community among its readers.

Click here to view our media kit/rate card.

Publisher and Sales Contacts:
Amy Birnbach
Group Publisher
Ph: 201-984-6265
Email: amy.birnbach@ubm.com

Sarah Mifsud
Account Manager
Digital Media
Ph: 203-523-7055
Email: sarah.mifsud@ubm.com

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.